Cell-free DNA (cfDNA) fragmentation patterns reflect epigenetic modifications and are promising biomarkers for early cancer detection. While integrating diverse fragmentomic signals can improve accuracy, high modality dimensionality, and limited samples challenge effective multimodal fusion. We present Early-Late fusion with Sample-Modality evaluation (ELSM), a two-stage neural network integrating 13 fragmentomic feature spaces with sample-wise modality evaluation to capture complementary signals. Across five datasets of 1994 samples from 10 cancer types, ELSM outperforms unimodal and advanced multimodal models for cancer detection and tissue-of-origin prediction, achieving an AUC of 0.972 for pan-cancer diagnosis and 0.922 in an independent gastric cancer cohort, with a median tissue-of-origin accuracy of 0.683. Analysis of key genomic regions identified by ELSM reveals robust interpretability aligned with known oncogenic pathways. ELSM provides a powerful and interpretable framework for integrative multi-omics analysis with strong potential for clinical translation in early cancer detection.

Using multi-omics data for clustering (cancer subtyping) is crucial for precision medicine research. Despite numerous methods having been proposed, current approaches either do not perform satisfactorily or lack biological interpretability, limiting the practical application of these methods. Based on the biological hypothesis that patients with the same subtype may exhibit similar dysregulated pathways, we developed an Iterative Pathway Fusion approach for enhanced Multi-omics Clustering (IPFMC), a novel multi-omics clustering method involving two data fusion stages. In the first stage, omics data are partitioned at each layer using pathway information, with crucial pathways iteratively selected to represent samples. Ultimately, the representation information from multiple pathways is integrated. In the second stage, similarity network fusion was applied to integrate the representation information from multiple omics. Comparative experiments with nine cancer datasets from The Cancer Genome Atlas (TCGA), involving systematic comparisons with 10 representative methods, reveal that IPFMC outperforms these methods. Additionally, the biological pathways and genes identified by our approach hold biological significance, affirming not only its excellent clustering performance but also its biological interpretability.

MOTIVATION: Classification of samples using biomedical omics data is a widely used method in biomedical research. However, these datasets often possess challenging characteristics, including high dimensionality, limited sample sizes, and inherent biases across diverse sources. These factors limit the performance of traditional machine learning models, particularly when applied to independent datasets. RESULTS: To address these challenges, we propose a novel classifier, Deep Centroid, which combines the stability of the nearest centroid classifier and the strong fitting ability of the deep cascade strategy. Deep Centroid is an ensemble learning method with a multi-layer cascade structure, consisting of feature scanning and cascade learning stages that can dynamically adjust the training scale. We apply Deep Centroid to three precision medicine applications-cancer early diagnosis, cancer prognosis, and drug sensitivity prediction-using cell-free DNA fragmentations, gene expression profiles, and DNA methylation data. Experimental results demonstrate that Deep Centroid outperforms six traditional machine learning models in all three applications, showcasing its potential in biological omics data classification. Furthermore, functional annotations reveal that the features scanned by the model exhibit biological significance, indicating its interpretability from a biological perspective. Our findings underscore the promising application of Deep Centroid in the classification of biomedical omics data, particularly in the field of precision medicine. AVAILABILITY AND IMPLEMENTATION: Deep Centroid is available at both github (github.com/xiexiexiekuan/DeepCentroid) and Figshare (https://figshare.com/articles/software/Deep_Centroid_A_General_Deep_Cascade_Classifier_for_Biomedical_Omics_Data_Classification/24993516).

The identification of cancer driver genes is crucial for early detection, effective therapy, and precision medicine of cancer. Cancer is caused by the dysregulation of several genes at various levels of regulation. However, current techniques only capture a limited amount of regulatory information, which may hinder their efficacy. In this study, we present IMI-driver, a model that integrates multi-omics data into eight biological networks and applies Multi-view Collaborative Network Embedding to embed the gene regulation information from the biological networks into a low-dimensional vector space to identify cancer drivers. We apply IMI-driver to 29 cancer types from The Cancer Genome Atlas (TCGA) and compare its performance with nine other methods on nine benchmark datasets. IMI-driver outperforms the other methods, demonstrating that multi-level network integration enhances prediction accuracy. We also perform a pan-cancer analysis using the genes identified by IMI-driver, which confirms almost all our selected candidate genes as known or potential drivers. Case studies of the new positive genes suggest their roles in cancer development and progression.

MOTIVATION: Drug combinations have exhibited promise in treating cancers with less toxicity and fewer adverse reactions. However, in vitro screening of synergistic drug combinations is time-consuming and labor-intensive because of the combinatorial explosion. Although a number of computational methods have been developed for predicting synergistic drug combinations, the multi-way relations between drug combinations and cell lines existing in drug synergy data have not been well exploited. RESULTS: We propose a multi-way relation-enhanced hypergraph representation learning method to predict anti-cancer drug synergy, named HypergraphSynergy. HypergraphSynergy formulates synergistic drug combinations over cancer cell lines as a hypergraph, in which drugs and cell lines are represented by nodes and synergistic drug-drug-cell line triplets are represented by hyperedges, and leverages the biochemical features of drugs and cell lines as node attributes. Then, a hypergraph neural network is designed to learn the embeddings of drugs and cell lines from the hypergraph and predict drug synergy. Moreover, the auxiliary task of reconstructing the similarity networks of drugs and cell lines is considered to enhance the generalization ability of the model. In the computational experiments, HypergraphSynergy outperforms other state-of-the-art synergy prediction methods on two benchmark datasets for both classification and regression tasks and is applicable to unseen drug combinations or cell lines. The studies revealed that the hypergraph formulation allows us to capture and explain complex multi-way relations of drug combinations and cell lines, and also provides a flexible framework to make the best use of diverse information. AVAILABILITY AND IMPLEMENTATION: The source data and codes of HypergraphSynergy can be freely downloaded from https://github.com/liuxuan666/HypergraphSynergy. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

BACKGROUND: The identification of prognostic genes that can distinguish the prognostic risks of cancer patients remains a significant challenge. Previous works have proven that functional gene sets were more reliable for this task than the gene signature. However, few works have considered the cross-talk among functional gene sets, which may result in neglecting important prognostic gene sets for cancer. RESULTS: Here, we proposed a new method that considers both the interactions among modules and the prognostic correlation of the modules to identify prognostic modules in cancers. First, dense sub-networks in the gene co-expression network of cancer patients were detected. Second, cross-talk between every two modules was identified by a permutation test, thus generating the module network. Third, the prognostic correlation of each module was evaluated by the resampling method. Then, the GeneRank algorithm, which takes the module network and the prognostic correlations of all the modules as input, was applied to prioritize the prognostic modules. Finally, the selected modules were validated by survival analysis in various data sets. Our method was applied in three kinds of cancers, and the results show that our method succeeded in identifying prognostic modules in all the three cancers. In addition, our method outperformed state-of-the-art methods. Furthermore, the selected modules were significantly enriched with known cancer-related genes and drug targets of cancer, which may indicate that the genes involved in the modules may be drug targets for therapy. CONCLUSIONS: We proposed a useful method to identify key modules in cancer prognosis and our prognostic genes may be good candidates for drug targets.

BACKGROUND: Protein-DNA interactions are essential for many biological processes. However, the structural mechanisms underlying these interactions are not fully understood. DNA binding proteins can be classified into double-stranded DNA binding proteins (DSBs) and single-stranded DNA binding proteins (SSBs), and they take part in different biological functions. DSBs usually act as transcriptional factors to regulate the genes' expressions, while SSBs usually play roles in DNA replication, recombination, and repair, etc. Understanding the binding specificity of a DNA binding protein is helpful for the research of protein functions. RESULTS: In this paper, we investigated the differences between DSBs and SSBs on surface tunnels as well as the OB-fold domain information. We detected the largest clefts on the protein surfaces, to obtain several features to be used for distinguishing the potential interfaces between SSBs and DSBs, and compared its structure with each of the six OB-fold protein templates, and use the maximal alignment score TM-score as the OB-fold feature of the protein, based on which, we constructed the support vector machine (SVM) classification model to automatically distinguish these two kinds of proteins, with prediction accuracy of 87%,83% and 83% for HOLO-set, APO-set and Mixed-set respectively. CONCLUSIONS: We found that they have different ranges of tunnel lengths and tunnel curvatures; moreover, the alignment results with OB-fold templates have also found to be the discriminative feature of SSBs and DSBs. Experimental results on 10-fold cross validation indicate that the new feature set are effective to describe DNA binding proteins. The evaluation results on both bound (DNA-bound) and non-bound (DNA-free) proteins have shown the satisfactory performance of our method.

BACKGROUND: Many classifiers which are constructed with chosen gene markers have been proposed to forecast the prognosis of patients who suffer from breast cancer. However, few of them has been applied in clinical practice because of the bad generalization, which results from the situation that markers selected by one method are very different from those obtained by another method, and thus such markers always lack discriminative capability in the other data sets. METHODS: In this work, a new ensemble classifier, on the basis of context specific miRNA regulation modules, has been proposed to forecast the metastasis risk of cancer sufferers. First, we defined all of the miRNAs which regulate the same context as a module that contains miRNAs and their regulating context, and applied the CoMi (Context-specific miRNA activity) score in order to illustrate a miRNA's effect which happened in a particular background; then the miRNA regulation modules with distinguishing abilities were detected and each of them was responsible for building a weak classifier separately; at last, by using majority voting strategy, we integrated all weak classifiers to establish an ensembled one that was applied to forecast the prognosis of patients who suffer from cancer. RESULTS: After comparing, the results on the cohorts containing over 1,000 samples showed that the proposed ensemble classifier is superior to other three classifiers based on miRNA expression profiles, mRNA expression profiles and CoMi activity patterns respectively. Significantly, our method outperforms the representative works. Moreover, the detected modules from different data sets show great stability (with p-value of 6.40e-08). For investigating the biological significance of those selected modules, case studies have been done by us and the results suggested that our method do help to reveal latent mechanism in metastasis of breast cancer. CONCLUSIONS: One context specific miRNA regulation module can uncover one critical biological process and its involved miRNAs that are related to the cancer outcome, and several modules together can help to study the biological mechanism in cancer metastasis, thus the classifer based on ensembling multiple classifers which were built with different context specific miRNA regulation modules has showed promising performances in terms with both prediction accuracy and generalization.

Many methods based on building classifiers by selecting gene markers have been proposed to predict breast cancer patient's outcome However, most of them suffer from the problem of poor robustness, which are mainly due to the fact that the overlap degree of gene markers derived by different methods is not high, hading that few of them are generalized and can be widely used for clinical practice. In this paper, we present a method based on context-specific miRNA regulation modules to predict distant metastasis in breast cancer. First, we describe the regulation activity of a miRNA on a specific context by using CoMi (Context-specific miRNA activity) score, based on which, several miRNAs regulate on the same context are regarded as a miRNA regulation module; then the discriminate regulation modules are selected and each is used to construct a classification model separately; finally, an ensemble classifier is established by combining all the models with a majority voting strategy. The evaluation experiment results show that our method performs better than previous works. In addition, the obtained discriminate modules show great stability across different data sets (withp-value of 1.119e-06).